Circulating Sclerostin: A New Parameter of Cardiovascular Risk in CKD-Patients

Chronic Kidney Disease (CKD) is an important risk factor for cardiovascular disease. A significantly higher cardiovascular risk has even been identified for minor renal dysfunction [1] – and dialysis patients are at a very high risk: it is well known that the cardiovascular risk of patients with End Stage Renal Disease (ESRD) is increased about 20- to 30-fold compared to people with normal kidney function [2].

Numerous studies have revealed an association between poor patients’ outcome and deranged circulating bone biomarkers in ESRD like FGF23, PTH or alkaline phosphatase. A novel factor involved in the so-called bone-vascular axis is sclerostin. A French study [3] has shown that sclerostin increases with the severity of CKD. The aim of the NECOSAD study, an observational prospective follow-up study in ESRD patients in The Netherlands, was to assess the effect of circulation sclerostin levels on mortality.

Read more